Washington Post Publisher Will Lewis Steps Down After Layoffs 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
LOS ANGELES, June 26, 2017 -- Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE MKT:IMUC) regarding possible violations of federal securities laws from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the June 30, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may do nothing and be an absent class member as well.
According to the Complaint, during the Class Period, ImmunoCellular issued materially false and/or misleading statements, and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish articles designed to unlawfully promote the Company; and that as a result of this scheme, the market was led to believe that the Company’s clinical studies for its product candidate (ICT-107) was going well and the share price was artificially inflated. Following this news, the Company’s stock price dropped materially, which harmed investors according to the Complaint. On April 10, 2017, the Securities & Exchange Commission announced enforcement actions against numerous individuals and entities, including ImmunoCellular, which engaged in stock promotion schemes.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles devoted to upholding shareholders’ rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and ethics rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
